Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07469891 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
A Phase 1 study, sponsored by Prelude Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT07469891 is a Phase 1 study that is actively recruiting participants, run by Prelude Therapeutics. The registered enrollment target is 100 participants.
The verdict
NCT07469891, a Phase 1 study, is actively recruiting participants, sponsored by Prelude Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE\[s\]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Interventions
- DRUG PRT12396
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2026-04-29 |
| Est. Completion | 2028-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07469891
The ClinicalTrials.gov registry entry for NCT07469891 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Prelude Therapeutics, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PRT12396 is the first listed.
NCT07469891 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07469891 about?
NCT07469891 is a clinical study titled "A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms". This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and r...
What is the current status of trial NCT07469891?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2026-04-29. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07469891?
The interventions under investigation include: PRT12396 (DRUG).
Who is sponsoring clinical trial NCT07469891?
This trial is sponsored by Prelude Therapeutics, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.